Thursday, July 16, 2026

11:15 AM - 1:15 PM

---

Details

Fibrosis is identified as a contributing factor in up to one third of all deaths. This pervasive, sometimes insidious influence is remarkably difficult to target with drugs. In this symposium we will focus on the characteristics of registered anti-fibrotic drugs, identifying their benefits and limitations. The anti-fibrotic drug pipeline will be reviewed, as will emerging concepts on ECM with immune and mesenchymal cells promoting progressive fibrosis-associated conditions.

---

Session chair